Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Growth 2026-2032
The global Anti-VEGF Drugs for Angiogenesis-related Disease market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
United States market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Anti-VEGF Drugs for Angiogenesis-related Disease players cover Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Anti-VEGF Drugs for Angiogenesis-related Disease Industry Forecast? looks at past sales and reviews total world Anti-VEGF Drugs for Angiogenesis-related Disease sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Drugs for Angiogenesis-related Disease sales for 2026 through 2032. With Anti-VEGF Drugs for Angiogenesis-related Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Drugs for Angiogenesis-related Disease industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Drugs for Angiogenesis-related Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Drugs for Angiogenesis-related Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Anti-VEGF Drugs for Angiogenesis-related Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Drugs for Angiogenesis-related Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Drugs for Angiogenesis-related Disease.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Anti-VEGF (vascular endothelial growth factor) drugs are a class of drugs that inhibit vascular endothelial growth factor (VEGF). They are mainly used to treat diseases related to angiogenesis, including tumors, eye diseases, etc.
United States market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Anti-VEGF Drugs for Angiogenesis-related Disease is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Anti-VEGF Drugs for Angiogenesis-related Disease players cover Roche, Bayer, Genentech, Novartis, Coherus BioSciences Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Anti-VEGF Drugs for Angiogenesis-related Disease Industry Forecast? looks at past sales and reviews total world Anti-VEGF Drugs for Angiogenesis-related Disease sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Drugs for Angiogenesis-related Disease sales for 2026 through 2032. With Anti-VEGF Drugs for Angiogenesis-related Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Drugs for Angiogenesis-related Disease industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Drugs for Angiogenesis-related Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anti-VEGF Drugs for Angiogenesis-related Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Anti-VEGF Drugs for Angiogenesis-related Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Drugs for Angiogenesis-related Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Drugs for Angiogenesis-related Disease.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Ranibizumab
- Brolucizumab
- Aflibercept
- Conbercept
- Faricimab
- Others
- Tumor
- Eye Diseases
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Bayer
- Genentech
- Novartis
- Coherus BioSciences Inc.
- Regeneron
- Qilu Pharmaceutical Co.,Ltd.
- Innovent Biologics
- Anke Biotechnology
- Shenzhen Kangzhe Pharmaceutical Co Ltd
- Chengdu Kanghong Pharmaceutical Group
- Rongchang Biology
- Youzhiyou Bio
- What is the 10-year outlook for the global Anti-VEGF Drugs for Angiogenesis-related Disease market?
- What factors are driving Anti-VEGF Drugs for Angiogenesis-related Disease market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Anti-VEGF Drugs for Angiogenesis-related Disease market opportunities vary by end market size?
- How does Anti-VEGF Drugs for Angiogenesis-related Disease break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Country/Region, 2021, 2025 & 2032
2.2 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Type
2.2.1 Ranibizumab
2.2.2 Brolucizumab
2.2.3 Aflibercept
2.2.4 Conbercept
2.2.5 Faricimab
2.2.6 Others
2.2.7 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
2.2.7.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
2.2.7.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2021-2026)
2.3 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Application
2.3.1 Tumor
2.3.2 Eye Diseases
2.3.3 Others
2.3.4 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
2.3.4.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2021-2026)
2.3.4.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Breakdown Data by Company
3.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Company (2021-2026)
3.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2021-2026)
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Company (2021-2026)
3.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2021-2026)
3.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2021-2026)
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Product Location Distribution
3.4.2 Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Geographic Region (2021-2026)
4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country/Region (2021-2026)
4.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Country/Region (2021-2026)
4.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.4 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.6 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country
5.1.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026)
5.1.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026)
5.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
5.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region
6.1.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2021-2026)
6.1.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2021-2026)
6.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
6.3 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease by Country
7.1.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026)
7.1.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026)
7.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
7.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease by Country
8.1.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026)
8.1.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026)
8.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
8.3 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.3 Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.4 Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Drugs for Angiogenesis-related Disease Distributors
11.3 Anti-VEGF Drugs for Angiogenesis-related Disease Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Forecast by Region
12.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Region (2027-2032)
12.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Type (2027-2032)
12.7 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Genentech
13.3.1 Genentech Company Information
13.3.2 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Genentech Main Business Overview
13.3.5 Genentech Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Coherus BioSciences Inc.
13.5.1 Coherus BioSciences Inc. Company Information
13.5.2 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Coherus BioSciences Inc. Main Business Overview
13.5.5 Coherus BioSciences Inc. Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Qilu Pharmaceutical Co.,Ltd.
13.7.1 Qilu Pharmaceutical Co.,Ltd. Company Information
13.7.2 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Qilu Pharmaceutical Co.,Ltd. Main Business Overview
13.7.5 Qilu Pharmaceutical Co.,Ltd. Latest Developments
13.8 Innovent Biologics
13.8.1 Innovent Biologics Company Information
13.8.2 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Innovent Biologics Main Business Overview
13.8.5 Innovent Biologics Latest Developments
13.9 Anke Biotechnology
13.9.1 Anke Biotechnology Company Information
13.9.2 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Anke Biotechnology Main Business Overview
13.9.5 Anke Biotechnology Latest Developments
13.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
13.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Company Information
13.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business Overview
13.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
13.11 Chengdu Kanghong Pharmaceutical Group
13.11.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.11.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
13.12 Rongchang Biology
13.12.1 Rongchang Biology Company Information
13.12.2 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Rongchang Biology Main Business Overview
13.12.5 Rongchang Biology Latest Developments
13.13 Youzhiyou Bio
13.13.1 Youzhiyou Bio Company Information
13.13.2 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Youzhiyou Bio Main Business Overview
13.13.5 Youzhiyou Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Anti-VEGF Drugs for Angiogenesis-related Disease by Country/Region, 2021, 2025 & 2032
2.2 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Type
2.2.1 Ranibizumab
2.2.2 Brolucizumab
2.2.3 Aflibercept
2.2.4 Conbercept
2.2.5 Faricimab
2.2.6 Others
2.2.7 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type
2.2.7.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
2.2.7.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Type (2021-2026)
2.2.7.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2021-2026)
2.3 Anti-VEGF Drugs for Angiogenesis-related Disease Segment by Application
2.3.1 Tumor
2.3.2 Eye Diseases
2.3.3 Others
2.3.4 Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application
2.3.4.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2021-2026)
2.3.4.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Breakdown Data by Company
3.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Company (2021-2026)
3.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2021-2026)
3.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Company (2021-2026)
3.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2021-2026)
3.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2021-2026)
3.3 Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company
3.4 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Product Location Distribution
3.4.2 Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
4.1 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Geographic Region (2021-2026)
4.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Anti-VEGF Drugs for Angiogenesis-related Disease Market Size by Country/Region (2021-2026)
4.2.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales by Country/Region (2021-2026)
4.2.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.4 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.5 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
4.6 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth
5 AMERICAS
5.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country
5.1.1 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026)
5.1.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026)
5.2 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
5.3 Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region
6.1.1 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2021-2026)
6.1.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2021-2026)
6.2 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
6.3 APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease by Country
7.1.1 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026)
7.1.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026)
7.2 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
7.3 Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease by Country
8.1.1 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026)
8.1.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026)
8.2 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026)
8.3 Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.3 Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
10.4 Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Anti-VEGF Drugs for Angiogenesis-related Disease Distributors
11.3 Anti-VEGF Drugs for Angiogenesis-related Disease Customer
12 WORLD FORECAST REVIEW FOR ANTI-VEGF DRUGS FOR ANGIOGENESIS-RELATED DISEASE BY GEOGRAPHIC REGION
12.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Market Size Forecast by Region
12.1.1 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Region (2027-2032)
12.1.2 Global Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Type (2027-2032)
12.7 Global Anti-VEGF Drugs for Angiogenesis-related Disease Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.1.3 Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.2.3 Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Genentech
13.3.1 Genentech Company Information
13.3.2 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.3.3 Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Genentech Main Business Overview
13.3.5 Genentech Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.4.3 Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Coherus BioSciences Inc.
13.5.1 Coherus BioSciences Inc. Company Information
13.5.2 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.5.3 Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Coherus BioSciences Inc. Main Business Overview
13.5.5 Coherus BioSciences Inc. Latest Developments
13.6 Regeneron
13.6.1 Regeneron Company Information
13.6.2 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.6.3 Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Regeneron Main Business Overview
13.6.5 Regeneron Latest Developments
13.7 Qilu Pharmaceutical Co.,Ltd.
13.7.1 Qilu Pharmaceutical Co.,Ltd. Company Information
13.7.2 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Qilu Pharmaceutical Co.,Ltd. Main Business Overview
13.7.5 Qilu Pharmaceutical Co.,Ltd. Latest Developments
13.8 Innovent Biologics
13.8.1 Innovent Biologics Company Information
13.8.2 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.8.3 Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Innovent Biologics Main Business Overview
13.8.5 Innovent Biologics Latest Developments
13.9 Anke Biotechnology
13.9.1 Anke Biotechnology Company Information
13.9.2 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.9.3 Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Anke Biotechnology Main Business Overview
13.9.5 Anke Biotechnology Latest Developments
13.10 Shenzhen Kangzhe Pharmaceutical Co Ltd
13.10.1 Shenzhen Kangzhe Pharmaceutical Co Ltd Company Information
13.10.2 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.10.3 Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business Overview
13.10.5 Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
13.11 Chengdu Kanghong Pharmaceutical Group
13.11.1 Chengdu Kanghong Pharmaceutical Group Company Information
13.11.2 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.11.3 Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Chengdu Kanghong Pharmaceutical Group Main Business Overview
13.11.5 Chengdu Kanghong Pharmaceutical Group Latest Developments
13.12 Rongchang Biology
13.12.1 Rongchang Biology Company Information
13.12.2 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.12.3 Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Rongchang Biology Main Business Overview
13.12.5 Rongchang Biology Latest Developments
13.13 Youzhiyou Bio
13.13.1 Youzhiyou Bio Company Information
13.13.2 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
13.13.3 Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Youzhiyou Bio Main Business Overview
13.13.5 Youzhiyou Bio Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Brolucizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Conbercept
Table 7. Major Players of Faricimab
Table 8. Major Players of Others
Table 9. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 10. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Table 11. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Type (2021-2026) & ($ million)
Table 12. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2021-2026)
Table 13. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale by Application (2021-2026) & (K Units)
Table 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2021-2026)
Table 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Application (2021-2026) & ($ million)
Table 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application (2021-2026)
Table 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2021-2026) & (US$/Unit)
Table 19. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Company (2021-2026) & (K Units)
Table 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2021-2026)
Table 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2021-2026) & ($ millions)
Table 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2021-2026)
Table 23. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company (2021-2026) & (US$/Unit)
Table 24. Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution and Sales Area
Table 25. Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
Table 26. Anti-VEGF Drugs for Angiogenesis-related Disease Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Geographic Region (2021-2026) & (K Units)
Table 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Geographic Region (2021-2026)
Table 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Geographic Region (2021-2026) & ($ millions)
Table 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region (2021-2026)
Table 33. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country/Region (2021-2026) & (K Units)
Table 34. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2021-2026)
Table 35. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026) & (K Units)
Table 38. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2021-2026)
Table 39. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026) & ($ millions)
Table 40. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 42. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2021-2026) & (K Units)
Table 43. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region (2021-2026)
Table 44. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2021-2026) & ($ millions)
Table 45. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 46. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 47. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026) & (K Units)
Table 48. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026) & ($ millions)
Table 49. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 50. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 51. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026) & (K Units)
Table 52. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2021-2026)
Table 53. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 54. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 56. Key Market Challenges & Risks of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 57. Key Industry Trends of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 58. Anti-VEGF Drugs for Angiogenesis-related Disease Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Anti-VEGF Drugs for Angiogenesis-related Disease Distributors List
Table 61. Anti-VEGF Drugs for Angiogenesis-related Disease Customer List
Table 62. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 63. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 67. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 68. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Type (2027-2032) & (K Units)
Table 73. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Type (2027-2032) & ($ millions)
Table 74. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Application (2027-2032) & (K Units)
Table 75. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Application (2027-2032) & ($ millions)
Table 76. Roche Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 77. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 78. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. Roche Main Business
Table 80. Roche Latest Developments
Table 81. Bayer Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 82. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 83. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Bayer Main Business
Table 85. Bayer Latest Developments
Table 86. Genentech Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 87. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 88. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Genentech Main Business
Table 90. Genentech Latest Developments
Table 91. Novartis Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 92. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 93. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Novartis Main Business
Table 95. Novartis Latest Developments
Table 96. Coherus BioSciences Inc. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 97. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 98. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Coherus BioSciences Inc. Main Business
Table 100. Coherus BioSciences Inc. Latest Developments
Table 101. Regeneron Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 102. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 103. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Regeneron Main Business
Table 105. Regeneron Latest Developments
Table 106. Qilu Pharmaceutical Co.,Ltd. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 107. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 108. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Qilu Pharmaceutical Co.,Ltd. Main Business
Table 110. Qilu Pharmaceutical Co.,Ltd. Latest Developments
Table 111. Innovent Biologics Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 112. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 113. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Innovent Biologics Main Business
Table 115. Innovent Biologics Latest Developments
Table 116. Anke Biotechnology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 117. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 118. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Anke Biotechnology Main Business
Table 120. Anke Biotechnology Latest Developments
Table 121. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 122. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 123. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business
Table 125. Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
Table 126. Chengdu Kanghong Pharmaceutical Group Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 127. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 128. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. Chengdu Kanghong Pharmaceutical Group Main Business
Table 130. Chengdu Kanghong Pharmaceutical Group Latest Developments
Table 131. Rongchang Biology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 132. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 133. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Rongchang Biology Main Business
Table 135. Rongchang Biology Latest Developments
Table 136. Youzhiyou Bio Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 137. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 138. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Youzhiyou Bio Main Business
Table 140. Youzhiyou Bio Latest Developments
Table 1. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Anti-VEGF Drugs for Angiogenesis-related Disease Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Ranibizumab
Table 4. Major Players of Brolucizumab
Table 5. Major Players of Aflibercept
Table 6. Major Players of Conbercept
Table 7. Major Players of Faricimab
Table 8. Major Players of Others
Table 9. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 10. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Table 11. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Type (2021-2026) & ($ million)
Table 12. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2021-2026)
Table 13. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Type (2021-2026) & (US$/Unit)
Table 14. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale by Application (2021-2026) & (K Units)
Table 15. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2021-2026)
Table 16. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Application (2021-2026) & ($ million)
Table 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application (2021-2026)
Table 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Application (2021-2026) & (US$/Unit)
Table 19. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Company (2021-2026) & (K Units)
Table 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company (2021-2026)
Table 21. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company (2021-2026) & ($ millions)
Table 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company (2021-2026)
Table 23. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Price by Company (2021-2026) & (US$/Unit)
Table 24. Key Manufacturers Anti-VEGF Drugs for Angiogenesis-related Disease Producing Area Distribution and Sales Area
Table 25. Players Anti-VEGF Drugs for Angiogenesis-related Disease Products Offered
Table 26. Anti-VEGF Drugs for Angiogenesis-related Disease Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Geographic Region (2021-2026) & (K Units)
Table 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Geographic Region (2021-2026)
Table 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Geographic Region (2021-2026) & ($ millions)
Table 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region (2021-2026)
Table 33. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country/Region (2021-2026) & (K Units)
Table 34. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2021-2026)
Table 35. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country/Region (2021-2026) & ($ millions)
Table 36. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country/Region (2021-2026)
Table 37. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026) & (K Units)
Table 38. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2021-2026)
Table 39. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026) & ($ millions)
Table 40. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 42. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Region (2021-2026) & (K Units)
Table 43. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region (2021-2026)
Table 44. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Region (2021-2026) & ($ millions)
Table 45. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 46. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 47. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026) & (K Units)
Table 48. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Country (2021-2026) & ($ millions)
Table 49. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 50. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 51. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Country (2021-2026) & (K Units)
Table 52. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2021-2026)
Table 53. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Type (2021-2026) & (K Units)
Table 54. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Application (2021-2026) & (K Units)
Table 55. Key Market Drivers & Growth Opportunities of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 56. Key Market Challenges & Risks of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 57. Key Industry Trends of Anti-VEGF Drugs for Angiogenesis-related Disease
Table 58. Anti-VEGF Drugs for Angiogenesis-related Disease Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Anti-VEGF Drugs for Angiogenesis-related Disease Distributors List
Table 61. Anti-VEGF Drugs for Angiogenesis-related Disease Customer List
Table 62. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 63. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Region (2027-2032) & (K Units)
Table 67. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 68. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Country (2027-2032) & (K Units)
Table 71. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Country (2027-2032) & ($ millions)
Table 72. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Type (2027-2032) & (K Units)
Table 73. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Type (2027-2032) & ($ millions)
Table 74. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Forecast by Application (2027-2032) & (K Units)
Table 75. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Forecast by Application (2027-2032) & ($ millions)
Table 76. Roche Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 77. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 78. Roche Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 79. Roche Main Business
Table 80. Roche Latest Developments
Table 81. Bayer Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 82. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 83. Bayer Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Bayer Main Business
Table 85. Bayer Latest Developments
Table 86. Genentech Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 87. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 88. Genentech Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Genentech Main Business
Table 90. Genentech Latest Developments
Table 91. Novartis Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 92. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 93. Novartis Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Novartis Main Business
Table 95. Novartis Latest Developments
Table 96. Coherus BioSciences Inc. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 97. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 98. Coherus BioSciences Inc. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Coherus BioSciences Inc. Main Business
Table 100. Coherus BioSciences Inc. Latest Developments
Table 101. Regeneron Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 102. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 103. Regeneron Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Regeneron Main Business
Table 105. Regeneron Latest Developments
Table 106. Qilu Pharmaceutical Co.,Ltd. Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 107. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 108. Qilu Pharmaceutical Co.,Ltd. Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Qilu Pharmaceutical Co.,Ltd. Main Business
Table 110. Qilu Pharmaceutical Co.,Ltd. Latest Developments
Table 111. Innovent Biologics Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 112. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 113. Innovent Biologics Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Innovent Biologics Main Business
Table 115. Innovent Biologics Latest Developments
Table 116. Anke Biotechnology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 117. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 118. Anke Biotechnology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Anke Biotechnology Main Business
Table 120. Anke Biotechnology Latest Developments
Table 121. Shenzhen Kangzhe Pharmaceutical Co Ltd Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 122. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 123. Shenzhen Kangzhe Pharmaceutical Co Ltd Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Shenzhen Kangzhe Pharmaceutical Co Ltd Main Business
Table 125. Shenzhen Kangzhe Pharmaceutical Co Ltd Latest Developments
Table 126. Chengdu Kanghong Pharmaceutical Group Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 127. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 128. Chengdu Kanghong Pharmaceutical Group Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. Chengdu Kanghong Pharmaceutical Group Main Business
Table 130. Chengdu Kanghong Pharmaceutical Group Latest Developments
Table 131. Rongchang Biology Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 132. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 133. Rongchang Biology Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Rongchang Biology Main Business
Table 135. Rongchang Biology Latest Developments
Table 136. Youzhiyou Bio Basic Information, Anti-VEGF Drugs for Angiogenesis-related Disease Manufacturing Base, Sales Area and Its Competitors
Table 137. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Product Portfolios and Specifications
Table 138. Youzhiyou Bio Anti-VEGF Drugs for Angiogenesis-related Disease Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. Youzhiyou Bio Main Business
Table 140. Youzhiyou Bio Latest Developments
LIST OF FIGURES
Figure 1. Picture of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 2. Anti-VEGF Drugs for Angiogenesis-related Disease Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2025)
Figure 10. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Ranibizumab
Figure 12. Product Picture of Brolucizumab
Figure 13. Product Picture of Aflibercept
Figure 14. Product Picture of Conbercept
Figure 15. Product Picture of Faricimab
Figure 16. Product Picture of Others
Figure 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type in 2026
Figure 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2021-2026)
Figure 19. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Tumor
Figure 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Tumor (2021-2026) & (K Units)
Figure 21. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Eye Diseases
Figure 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Eye Diseases (2021-2026) & (K Units)
Figure 23. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Others
Figure 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Others (2021-2026) & (K Units)
Figure 25. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2025)
Figure 26. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application in 2026
Figure 27. Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Company in 2026 (K Units)
Figure 28. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company in 2026
Figure 29. Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company in 2026 ($ millions)
Figure 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company in 2026
Figure 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 34. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 35. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 36. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 37. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 38. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2026
Figure 42. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2021-2026)
Figure 43. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 44. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 45. United States Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region in 2026
Figure 50. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Region (2021-2026)
Figure 51. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 52. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 53. China Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 57. India Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2026
Figure 61. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2021-2026)
Figure 62. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 63. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 64. Germany Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 65. France Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 72. Egypt Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease in 2026
Figure 78. Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 79. Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 80. Channels of Distribution
Figure 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Forecast by Region (2027-2032)
Figure 82. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 2. Anti-VEGF Drugs for Angiogenesis-related Disease Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2025)
Figure 10. Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Ranibizumab
Figure 12. Product Picture of Brolucizumab
Figure 13. Product Picture of Aflibercept
Figure 14. Product Picture of Conbercept
Figure 15. Product Picture of Faricimab
Figure 16. Product Picture of Others
Figure 17. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type in 2026
Figure 18. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Type (2021-2026)
Figure 19. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Tumor
Figure 20. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Tumor (2021-2026) & (K Units)
Figure 21. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Eye Diseases
Figure 22. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Eye Diseases (2021-2026) & (K Units)
Figure 23. Anti-VEGF Drugs for Angiogenesis-related Disease Consumed in Others
Figure 24. Global Anti-VEGF Drugs for Angiogenesis-related Disease Market: Others (2021-2026) & (K Units)
Figure 25. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sale Market Share by Application (2025)
Figure 26. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Application in 2026
Figure 27. Anti-VEGF Drugs for Angiogenesis-related Disease Sales by Company in 2026 (K Units)
Figure 28. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Company in 2026
Figure 29. Anti-VEGF Drugs for Angiogenesis-related Disease Revenue by Company in 2026 ($ millions)
Figure 30. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Company in 2026
Figure 31. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Geographic Region (2021-2026)
Figure 32. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Geographic Region in 2026
Figure 33. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 34. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 35. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 36. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 37. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 38. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 39. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales 2021-2026 (K Units)
Figure 40. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue 2021-2026 ($ millions)
Figure 41. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2026
Figure 42. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2021-2026)
Figure 43. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 44. Americas Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 45. United States Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 46. Canada Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 47. Mexico Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 48. Brazil Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 49. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Region in 2026
Figure 50. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Region (2021-2026)
Figure 51. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 52. APAC Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 53. China Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 54. Japan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 55. South Korea Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 56. Southeast Asia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 57. India Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 58. Australia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 59. China Taiwan Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 60. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country in 2026
Figure 61. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share by Country (2021-2026)
Figure 62. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 63. Europe Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 64. Germany Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 65. France Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 66. UK Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 67. Italy Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 68. Russia Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 69. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Country (2021-2026)
Figure 70. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Type (2021-2026)
Figure 71. Middle East & Africa Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share by Application (2021-2026)
Figure 72. Egypt Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 73. South Africa Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 74. Israel Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 75. Turkey Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 76. GCC Countries Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Growth 2021-2026 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease in 2026
Figure 78. Manufacturing Process Analysis of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 79. Industry Chain Structure of Anti-VEGF Drugs for Angiogenesis-related Disease
Figure 80. Channels of Distribution
Figure 81. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Forecast by Region (2027-2032)
Figure 82. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Region (2027-2032)
Figure 83. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Type (2027-2032)
Figure 84. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Type (2027-2032)
Figure 85. Global Anti-VEGF Drugs for Angiogenesis-related Disease Sales Market Share Forecast by Application (2027-2032)
Figure 86. Global Anti-VEGF Drugs for Angiogenesis-related Disease Revenue Market Share Forecast by Application (2027-2032)
